Lb Pharmaceuticals (LBRX) Total Liabilities (2024 - 2026)

Lb Pharmaceuticals' Total Liabilities history runs 3 years deep, the most recent figure standing at $14.8 million for Q1 2026.

• In Q1 2026, Total Liabilities changed N/A year-over-year to $14.8 million; the TTM figure through Mar 2026 stood at $14.8 million (changed N/A YoY), while the FY2025 annual figure was $11.6 million, down 15.94% from the prior year.
• Total Liabilities for Q1 2026 stood at $14.8 million, up from $11.6 million in the prior quarter.
• The five-year high for Total Liabilities was $14.8 million in Q1 2026, with the low at $10.5 million in Q3 2025.
• The 3-year median for Total Liabilities is $12.7 million (2024), against an average of $12.7 million.
• Peak annual rise in Total Liabilities reached 15.94% in 2025, while the deepest fall reached 15.94% in 2025.
• Lb Pharmaceuticals' Total Liabilities stood at $13.8 million in 2024, then retreated by 15.94% to $11.6 million in 2025, then climbed by 27.23% to $14.8 million in 2026.
• Business Quant data shows LBRX's Total Liabilities at $14.8 million in Q1 2026, $11.6 million in Q4 2025, and $10.5 million in Q3 2025.